Condition: Primary Membranous Nephropathy · Sponsor: Climb Bio, Inc.
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
This description comes directly from the study's public registry record.
Climb Bio Study Director · +1 866 857 2596 · clinicaltrials@climbbio.com
Always discuss trial participation with your own doctor first.
| Climb Bio Investigative Site #110 | Denver, Colorado, United States | Recruiting |
| Climb Bio Investigative Site #105 | Orlando, Florida, United States | Recruiting |
| Climb Bio Investigative Site #108 | Atlanta, Georgia, United States | Recruiting |
| Climb Bio Investigative Site #106 | Indianapolis, Indiana, United States | Recruiting |
| Climb Bio Investigative Site #111 | Boston, Massachusetts, United States | Not Yet Recruiting |
| Climb Bio Investigative Site #101 | Clifton Park, New York, United States | Recruiting |
| Climb Bio Investigative Site #104 | Sherman, Texas, United States | Recruiting |
| Climb Bio Investigative Site# 602 | Buenos Aires, Argentina | Recruiting |
| Climb Bio Investigative Site# 603 | Buenos Aires, Argentina | Recruiting |
| Climb Bio Investigative Site #601 | CABA, Argentina | Recruiting |
| Climb Bio Investigative Site #604 | CABA, Argentina | Recruiting |
| Climb Bio Investigative Site #606 | Santa Fe, Argentina | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096843